Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine if Proton Therapy can provide effective and safe treatment for Malignant Peripheral Nerve Sheath Tumors of the spine and Neurofibromas of the spine.


Clinical Trial Description

Proton therapy may provide the benefits of local control or palliation, while reducing the risk associated with photon radiation, by delivering therapeutic doses to a well-defined target area with significant reduction in the integral dose. A dosimetry comparison of protons and photons at the University of Florida Proton Therapy Institute confirmed the feasibility of proton irradiation of these tumors with less exposure of normal tissue to radiation than expected with photon techniques. This reduced radiation exposure to uninvolved normal tissues is expected to decrease the risk of radiation-induced second malignancies and neoplasms. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01567787
Study type Interventional
Source University of Florida
Contact
Status Withdrawn
Phase N/A
Start date June 2013
Completion date August 2015

See also
  Status Clinical Trial Phase
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Recruiting NCT05891847 - Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia
Recruiting NCT06322342 - Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent Phase 2
Completed NCT00314119 - Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
Terminated NCT00716469 - Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas Phase 1
Active, not recruiting NCT03820778 - Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 N/A
Active, not recruiting NCT00924196 - Natural History Study of Patients With Neurofibromatosis Type I
Recruiting NCT05199376 - Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1 N/A
Completed NCT01031901 - Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) Phase 1